Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix 3-month regimen versus goserelin in prostate cancer requiring androgen deprivation therapy
2008-005276-27Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- May 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing Degarelix three-month dosing regimen with Goserelin acetate (2 arms). Primary endpoint: Cumulative probability of testosterone suppression to castrate level. Started May 2009; status: completed.
02
Drugs
degarelixgoserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-005276-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005276-27.